TY - JOUR
T1 - The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea
T2 - Results of a Korean Expert Consensus
AU - Park, Eun Jung
AU - Kim, Hyungjin
AU - Jung, Seung Min
AU - Sung, Yoon Kyoung
AU - Baek, Han Joo
AU - Lee, Jisoo
N1 - Publisher Copyright:
Copyright © 2020 by The Korean College of Rheumatology. All rights reserved.
PY - 2020/1
Y1 - 2020/1
N2 - Biological disease-modifying antirheumatic drugs (bDMARDs) are highly effective agents for the treatment of inflammatory arthritis; however, they also possess a potential risk for serious infection. Recently, with the rapid expansion of the bDMARDs market in Korea, reports of serious adverse events related to the agents have also increased, necessitating guidance for the use of bDMARDs. Current work entitled, “Expert Consensus for the Use of bDMARDs Drugs for Inflammatory Arthritis in Korea,” is the first to describe the appropriate use of bDMARDs in the management of inflammatory arthritis in Korea, with an aim to provide guidance for the local medical community to improve the quality of clinical care. Twelve consensus statements regarding the use of bDMARDs for the management of rheumatoid arthritis and ankylosing spondylitis were generated. In this review, we provide detailed guidance on bDMARDs use based on expert consensus, including who should prescribe, the role of education, indications for use, and monitoring strategies for safety.
AB - Biological disease-modifying antirheumatic drugs (bDMARDs) are highly effective agents for the treatment of inflammatory arthritis; however, they also possess a potential risk for serious infection. Recently, with the rapid expansion of the bDMARDs market in Korea, reports of serious adverse events related to the agents have also increased, necessitating guidance for the use of bDMARDs. Current work entitled, “Expert Consensus for the Use of bDMARDs Drugs for Inflammatory Arthritis in Korea,” is the first to describe the appropriate use of bDMARDs in the management of inflammatory arthritis in Korea, with an aim to provide guidance for the local medical community to improve the quality of clinical care. Twelve consensus statements regarding the use of bDMARDs for the management of rheumatoid arthritis and ankylosing spondylitis were generated. In this review, we provide detailed guidance on bDMARDs use based on expert consensus, including who should prescribe, the role of education, indications for use, and monitoring strategies for safety.
KW - Ankylosing spondylitis
KW - Expert consensus
KW - Inflammatory arthritis
KW - Rheumatoid arthritis
KW - bDMARDs
UR - http://www.scopus.com/inward/record.url?scp=85089887523&partnerID=8YFLogxK
U2 - 10.4078/jrd.2020.27.1.4
DO - 10.4078/jrd.2020.27.1.4
M3 - Review article
AN - SCOPUS:85089887523
SN - 2093-940X
VL - 27
SP - 4
EP - 21
JO - Journal of Rheumatic Diseases
JF - Journal of Rheumatic Diseases
IS - 1
ER -